Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2230279 | 0.93 | ALDH1A1 (0.65) | LTA4HKDM4ETSHRALDH1A1HTT | |
| SCHEMBL14578276 | 0.88 | ALDH1A1 (0.69) | LTA4HKDM4ETSHRTP53ALDH1A1 | |
| SCHEMBL3401693 | 0.87 | HTR2C (0.55) | LTA4HKDM4ETSHRTP53ALDH1A1 | |
| SCHEMBL264157 | 0.86 | LTA4H (0.81) | LTA4HKDM4ETSHRALDH1A1HTT | |
| SCHEMBL3216190 | 0.85 | LTA4H (0.79) | LTA4HKDM4ETSHRALDH1A1HTT | |
| SCHEMBL3209561 | 0.85 | LTA4H (0.79) | LTA4HKDM4ETSHRALDH1A1HTT | |
| SCHEMBL5443488 | 0.84 | ALDH1A1 (0.62) | LTA4HKDM4ETSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL3206091 | 0.84 | KMT2A (0.68) | LTA4HKDM4ETSHRTP53ALDH1A1 | |
| SCHEMBL109617 | 0.83 | LTA4H (0.59) | LTA4HKDM4ETSHRTP53ALDH1A1 | |
| SCHEMBL8148219 | 0.82 | ALDH1A1 (0.63) | LTA4HKDM4ETSHRTP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023018472-A9 | AMINOARYL-INTEGRIN AGONISTS COMPOUNDS | TEXAS HEART INSTITUTE (US) | 2023-07-13 | — | — | WO | claimed |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | HANMI PHARM. CO., LTD. (KR) | 2025-11-25 | — | — | US | disclosed |
| CN-113365996-B | Imidazole pyridine derivative compound and pharmaceutical composition | 韩美药品株式会社 | 2024-09-03 | — | — | CN | disclosed |
| WO-2022199589-A1 | PYRIMIDINE DERIVATIVES | 南京明德新药研发有限公司 | 2022-09-29 | — | — | WO | disclosed |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-20220098205-A1 | IMIDAZOPYRIDINE DERIVATIVE COMPOUNDS AND USE OF SAME | HANMI PHARM. CO., LTD. (KR) | 2022-03-31 | — | — | US | disclosed |
| EP-3907225-A1 | IMIDAZOPYRIDINE DERIVATIVE COMPOUNDS AND USE OF SAME | Hanmi Pharm. Co., Ltd. (KR) | 2021-11-10 | — | — | EP | disclosed |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | CELGENE CAR LLC (BM) | 2020-11-10 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| EP-1294695-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6511980-B2 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-01-28 | — | — | US | disclosed |
| EP-0233461-B2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 2002-05-29 | — | — | EP | disclosed |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-31 | — | — | US | disclosed |
| WO-2001085694-A2 | SUBSTITUTED DIAMIDE DERIVATIVES USEFUL AS MOTILIN ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-11-15 | — | — | WO | disclosed |
| US-5556969-A | Benzodiazepine derivatives | MERCK SHARP & DOHME LTD. (GB) | 1996-09-17 | — | — | US | disclosed |
| EP-0233461-B1 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 1996-03-20 | — | — | EP | disclosed |
| US-4876252-A | ADMINISTERING ANTIASTHMATIC OR ANTIALLERGEN | AMERICAN CYANAMID COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
| US-4788195-A | TREATING ASTHMA, ALLERGIC DISEASES, INFLAMMATION AND DIABETES IN MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1988-11-29 | — | — | US | disclosed |
| EP-0233461-A2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID COMPANY (US) | 1987-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098205-A1 | IMIDAZOPYRIDINE DERIVATIVE COMPOUNDS AND USE OF SAME | KDM1A, KDM1B, KDM2A | LTA4H 1998/4885KDM4E 20/4885TSHR 4562/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | LTA4H 3529/4885KDM4E 866/4885TSHR 3159/4885 |
| US-20020013352-A1 | For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder | MLNR, GIPR, NPY1R | LTA4H 2264/4885KDM4E 2241/4885TSHR 185/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | LTA4H 3109/4885KDM4E 1613/4885TSHR 1825/4885 |
| US-10828300-B2 | Substituted 2,4-diaminopyrimidines as kinase inhibitors | ABL1, DCK, ERBB2 | LTA4H 4366/4885KDM4E 472/4885TSHR 3113/4885 |
| US-12479845-B2 | Imidazopyridine derivative compounds and use of same | KDM1A, KDM1B, KDM2A | LTA4H 1998/4885KDM4E 20/4885TSHR 4562/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LTA4H 1373/4885KDM4E 1645/4885TSHR 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.